Send us Fan Mail

Welcome to  our second episode of the Summer 23 season.  Awhile back we introduced  the new series  under the  brand #OMBCLShorts.    As the title implies, these are shorter episodes. Our second OMBCL Shorts features Dr. Erika Hamilton answering questions about her top takeaways from ASCO23.  In this 20-minute interview we covered important updates on the CDK4/6 inhibitors for both early-stage and metastatic breast cancer, as well as research on a new HER3 ADC and the first AKT inhibitor for MBC.
Listen in, enjoy, and let us know what you think by sending us a message on Twitter, Facebook, or Instagram! @ourmbclife

And don't forget to rate and review the podcast! Thanks so much for listening! 

We’re so happy you joined us! If this conversation resonated with you please share it with someone who might need it. Don't forget to like and subscribe here to follow us on your favorite podcast platform so you never miss an episode. You can find more episodes, resources and ways to get involved on our website Our MBC Life. Have a topic you’d like us to cover? Email us at ourmbclife@sharecancersupport.org. And don’t forget to follow us on our socials @ourmbclife. 

Remember you are not alone.